Short answer: only two compounds on the usual “best peptides for fat loss” list have large human trials behind them — tirzepatide and semaglutide — and both are prescription medicines, not research peptides. Tesamorelin has real trial data but only for shrinking deep abdominal fat in one specific patient group. AOD-9604 and MOTS-c, the two most heavily marketed as “fat burners,” have never shown fat loss in a human trial at all.
That gap between what is marketed and what is evidenced is the whole story on this topic. Below: what each compound actually did in studies, how much, over how long, what happened when people stopped, and where the numbers came from.
Comparison at a glance
| Peptide | Best documented result | Studied in | Evidence tier | Key caveat |
|---|---|---|---|---|
| Tirzepatide (GIP/GLP-1) | −20.9% body weight at 72 weeks (15 mg) vs −3.1% placebo | 2,539 adults with obesity, phase 3 | Strong human RCT — approved (Zepbound) | Prescription medicine; GI side effects; regain after stopping |
| Semaglutide (GLP-1) | −14.9% body weight at 68 weeks vs −2.4% placebo | 1,961 adults with overweight/obesity, phase 3 | Strong human RCT — approved (Wegovy) | Prescription medicine; GI side effects; two-thirds of loss regained a year after stopping |
| Tesamorelin (GHRH analog) | ~15.4% reduction in visceral fat; no meaningful overall weight loss | Adults with HIV-associated abdominal fat accumulation | Strong human RCT — but narrow | Approved for HIV lipodystrophy only; visceral fat re-accumulates off-treatment |
| AOD-9604 (GH fragment 176–191) | Weight and fat reduction in obese mice | Rodents; human phase 2 trials never led to approval | Preclinical for fat loss | Not approved for obesity anywhere; prohibited in sport by WADA |
| MOTS-c (mitochondrial peptide) | Improved glucose handling and reduced fat accumulation in mice | Cells and rodents; human data is observational only | Preclinical / mechanistic | No trial has ever given MOTS-c to humans to induce fat loss |
How much fat loss do the trials actually show?
Headline percentages get quoted constantly without the conditions attached. Here are the conditions.
Tirzepatide. In the phase 3 SURMOUNT-1 trial, mean weight change at 72 weeks was −15.0%, −19.5% and −20.9% across the 5, 10 and 15 mg doses versus −3.1% for placebo; 91% of the highest-dose group lost at least 5% of body weight (DOI: 10.1056/NEJMoa2206038). A separate phase 3 trial in Chinese adults reproduced double-digit reductions (DOI: 10.1001/jama.2024.9217), and a 2024 network meta-analysis ranked tirzepatide as the most effective anti-obesity pharmacotherapy tested, ahead of semaglutide.
Semaglutide. In STEP 1, mean weight change at 68 weeks was −14.9% versus −2.4% for placebo — a treatment difference of 12.4 percentage points. Broken down by responder rates: 86.4% lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%, against 31.5%, 12.0% and 4.9% on placebo (DOI: 10.1056/NEJMoa2032183). Those responder figures matter more than the average: half the group did not reach 15%.
Tesamorelin. A pooled analysis of two phase 3 trials in people with HIV-associated abdominal fat accumulation showed roughly a 15.4% reduction in visceral adipose tissue versus placebo, with no clinically significant change in subcutaneous fat and no meaningful overall weight loss (DOI: 10.1210/jc.2010-0490). This is the clearest example on the page of why “fat loss” and “weight loss” are not interchangeable.
AOD-9604 and MOTS-c. There is no human fat-loss number to report, because no trial has produced one. AOD-9604 reduced body weight and fat and increased lipolytic sensitivity in obese mice (DOI: 10.1210/endo.142.12.8522) and advanced into human phase 2 obesity trials, but was never approved as an anti-obesity therapy and is now prohibited in sport by the World Anti-Doping Agency (DOI: 10.1002/dta.1715). MOTS-c enhances glucose handling and activates AMPK in animal and cell studies and can increase brown-fat activity in mice (DOI: 10.1016/j.freeradbiomed.2016.05.015; DOI: 10.3389/fendo.2023.1120533); the human evidence is observational — plasma MOTS-c rises with exercise and correlates with fat-mass reduction — not trials of administering it.
How long did it take in the trials?
The single most misleading thing about the headline figures is the timescale. Nobody in these trials lost 20% in a month.
- The trials ran 68 to 72 weeks — that is roughly 16 to 17 months. The −20.9% figure for tirzepatide is a 72-week endpoint, not a starting rate.
- Dose escalation eats the first months. STEP 1 included 16 weeks of dose escalation before the full 2.4 mg weekly dose was reached (DOI: 10.1111/dom.14725). That is nearly four months before the studied dose was even in place.
- Weight-loss curves flatten. In both trial programs, the steepest loss occurred in the earlier phase and the curve approached a plateau toward the endpoint. Extrapolating an early rate forward produces numbers no trial has ever recorded.
- Tesamorelin’s endpoint was visceral fat on imaging, measured over 26 weeks — a different measurement on a different clock.
What happened when people stopped?
This is the question the marketing never covers, and there is a clean answer for semaglutide.
In the STEP 1 trial extension, 327 participants were followed for a further year after all treatment — drug and lifestyle intervention — was withdrawn at week 68. Mean weight loss over the treatment phase had been 17.3%. By week 120, participants had regained 11.6 percentage points of that loss, leaving a net 5.6% below their starting weight; the placebo group regained 1.9 points, ending at a net 0.1%. Most of the cardiometabolic improvements reverted toward baseline as well. The authors’ summary: participants regained about two-thirds of their prior weight loss within a year of stopping (DOI: 10.1111/dom.14725).
An earlier withdrawal analysis pointed the same way: in STEP 4, participants who continued semaglutide lost a further 7.9% while those switched to placebo regained 6.9% — a 14.8 percentage-point divergence (DOI: 10.1001/jama.2021.3224). Tesamorelin behaves the same way in its own domain: visceral fat re-accumulates once treatment ends (DOI: 10.2165/11202240-000000000-00000).
The pattern across every compound here with real data is that the effect lasts as long as the exposure does. That has direct consequences for how the risk-benefit picture should be read, since it implies indefinite use rather than a course.
“Fat loss” and “weight loss” are not the same measurement
Most of the figures above are body weight on a scale. Body weight is fat, lean tissue, water and gut contents together. Three distinctions change the interpretation:
- Visceral vs subcutaneous fat. Tesamorelin reduced visceral fat by ~15.4% while leaving subcutaneous fat essentially unchanged and producing no meaningful weight change (DOI: 10.1210/jc.2010-0490). On a scale, that looks like nothing happened. On imaging, the metabolically relevant depot moved.
- Lean mass travels with weight loss. Any substantial weight loss — drug-induced, surgical or dietary — includes lean tissue, and the proportion is largely a function of how much total weight is lost. We cover the DEXA data separately in do GLP-1 peptides cause muscle loss?
- Body composition is rarely the endpoint. Most large obesity trials are powered for percentage body weight, not fat mass. When a study reports “weight loss,” it usually has not separated the compartments at all.
If the goal is specifically fat, the measurement that answers it is DEXA or imaging, not the scale — and most of the compounds marketed for “fat loss” have never been measured that way in humans.
What the side-effect profiles look like
Effect sizes only mean something next to tolerability, and here the evidence is as uneven as the efficacy data.
For the GLP-1 compounds, nausea and diarrhoea were the most common adverse events, typically transient and mild-to-moderate, subsiding over time; 4.5% of the semaglutide group discontinued for gastrointestinal reasons versus 0.8% on placebo (DOI: 10.1056/NEJMoa2032183). These are medicines with defined labels, monitoring, and post-marketing surveillance behind those numbers.
For AOD-9604 and MOTS-c the honest statement is that no comparable safety dataset exists for the way they are actually used. There is no approved label, no adverse-event reporting system, and — for material bought outside a regulated supply chain — no guarantee that the identity, purity or quantity in the vial matches what is printed on it. That last point is not a footnote: an unknown quantity of an unknown substance has no risk profile at all.
What the evidence actually supports
Being blunt about the tiers: only semaglutide and tirzepatide have strong, large-scale human RCT evidence for reducing body weight, and both are approved prescription medicines rather than “research peptides” in practice. Tesamorelin has solid human trial data, but only for shrinking visceral fat in a specific clinical population — not for general fat loss, and the effect reverses when stopped. AOD-9604 and MOTS-c are, for fat loss, essentially preclinical: interesting mechanisms in animals with no convincing human weight-loss trials behind them. “Most discussed online” is close to the inverse of “best evidenced.” None of this ranks a best choice for any individual — it maps where the science currently stands.
Important limitations
- Research-use-only. The compounds discussed here are covered as research chemicals. This is educational information, not medical advice and not a protocol to follow.
- Most are not approved for fat loss. Tesamorelin is approved only for HIV lipodystrophy; AOD-9604 and MOTS-c are not approved anti-obesity therapies; semaglutide and tirzepatide are prescription-only medicines used under clinical supervision, and research-grade material is never the approved product.
- Trial averages are not personal predictions. Efficacy figures come from controlled trials in defined populations and do not predict outcomes, side effects or interactions for any specific person.
- Talk to a qualified healthcare professional before making any decision about weight, metabolic health or any substance. For unit-conversion and reconstitution math in a research context only, see the peptide dosage calculator.
FAQ
Which peptide has the strongest evidence for fat loss?
By trial quality and size, tirzepatide and semaglutide, and a 2024 network meta-analysis ranked tirzepatide highest for weight reduction. Both are approved prescription medicines, not over-the-counter research peptides, and this is not a recommendation to use either.
How much weight did people actually lose in the trials?
At 72 weeks on tirzepatide 15 mg, mean weight change was −20.9% versus −3.1% on placebo (DOI: 10.1056/NEJMoa2206038). At 68 weeks on semaglutide 2.4 mg it was −14.9% versus −2.4%, with 50.5% of participants losing at least 15% of body weight (DOI: 10.1056/NEJMoa2032183). Those are group averages across more than a year, not individual guarantees.
How long does it take to see results?
The published endpoints are 68 and 72 weeks. STEP 1 alone spent its first 16 weeks escalating the dose (DOI: 10.1111/dom.14725). Any claim built on a short timeframe is extrapolating past what the trials measured.
Do you regain the weight if you stop?
In the STEP 1 extension, participants regained about two-thirds of their lost weight in the year after treatment was withdrawn, and most cardiometabolic improvements reverted toward baseline (DOI: 10.1111/dom.14725). Tesamorelin’s visceral-fat reduction also reverses off-treatment.
Are AOD-9604 and MOTS-c “proven” for fat loss?
No. Their fat-loss data are largely from rodents and cell studies. AOD-9604 was never approved for obesity and is banned in sport; MOTS-c has no human trials testing it as a fat-loss treatment. Presenting them as proven human fat-loss agents would be inaccurate.
Why is tesamorelin listed if it’s not a general weight-loss drug?
Because it is frequently searched alongside “fat loss” and does have strong human data — but specifically for reducing visceral abdominal fat in HIV-associated lipodystrophy, with fat re-accumulating after treatment stops. It is the clearest illustration of why the endpoint and population behind a study matter as much as the headline.
Do these peptides burn fat specifically, or just weight?
Mostly weight. Large obesity trials are powered for percentage body weight, which combines fat, lean tissue and water. Tesamorelin is the exception that measured a fat compartment directly. For what happens to lean mass, see do GLP-1 peptides cause muscle loss?
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. DOI: 10.1056/NEJMoa2206038
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. DOI: 10.1111/dom.14725
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021. DOI: 10.1001/jama.2021.3224
- Falutz J, et al. Effects of tesamorelin on visceral adipose tissue: pooled phase 3 analysis. J Clin Endocrinol Metab. 2010. DOI: 10.1210/jc.2010-0490
- Tesamorelin review. Drugs. DOI: 10.2165/11202240-000000000-00000
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001. DOI: 10.1210/endo.142.12.8522
- AOD-9604 detection in doping control. Drug Test Anal. DOI: 10.1002/dta.1715
- MOTS-c and metabolic regulation. Free Radic Biol Med. 2016. DOI: 10.1016/j.freeradbiomed.2016.05.015
- MOTS-c review. Front Endocrinol. 2023. DOI: 10.3389/fendo.2023.1120533
Research-use-only. Sources are peer-reviewed literature indexed in PubMed and ClinicalTrials.gov. This overview is educational and is not a substitute for professional medical guidance.
